Nordic Life Science 1
APOTEK PRODUKTION & LABORATORIER ADVERTORIAL whic
h had long been listed as backlogged items. Discussions are also ongoing concerning extending APL’s social responsibility to preparedness tasks. In the event of war or an emergency, APL is able to fulfil a very important function that can help to guarantee the supply of medicines even during an unstable world situation. APL’s social mission provides invaluable benefit to patients, healthcare and society For over 40 years, Apotek Produktion & Laboratorier, APL, together with the healthcare sector, has developed and manufactured extemporaneous medicines for individually adapted treatment. APL’s unique mandate contributes critical societal benefit on a daily basis. By manufacturing medicines for patients who, for various reasons, are unable to use the medicines that are available on the market, APL helps to improve and save lives on a daily basis. APL IS A STATE-OWNED company and one of Europe’s leading companies in the manufacture of extemporaneous medicines. Once prescription of an extemporaneous medicine becomes more extensive, that drug can then be supplied as a stock preperation. “Our social commission entails a responsibility to develop and supply a medically suitable and quality-assured range of stock prepaFACTS APL is one of Europe’s leading companies in the manufacture of extemporaneous and stock preparations. We work on behalf of society and other pharmaceutical companies to create the greatest possible benefit to patients. Our vision is to make a difference for patients with specific needs. Our workforce of just over 500 employees produces medicines that improve and save lives. Forty years’ experience of extemporaneous medicines Extemporaneous medicines are prescribed when a licensed drug containing a desired substance is not available, when the right strength or pharmaceutical form is not available, or if the licensed drug contains a substance to which the patient is hyper-sensitive. APL represents the link between the pharmaceutical companies and the patient when the commercial suppliers are unable to supply what is required to each individual patient. During the Covid-19 pandemic APL was quick to appreciate the needs of emergency wards for analgesics, among other things, rations and extemporaneous medicines, which involves individually adapting a medicine for individual patients. We work on behalf of society and other pharmaceutical companies to create the greatest possible patient benefit,” explains Erik Haeffler, CEO of APL. Unique and extensive range APL also has over 30 years’ experience as an established contract manufacturer within the Life Science sector, providing both the pharmaceutical and analytical development and manufacture of both clinical investigational material and commercial products. From 4 manufacturing facilities located in Sweden we serve our clients with products and services tailored to the global markets. The facilities are operating in full EU GMP compliance as well as other key market authorisations like FDA (US) and ANVISA (Brazil). In all, this means that APL has a breadth that makes our collective offer highly competitive. “Factors that makes us unique in the CDMO sector are our expertise in small to mid-sized volumes and our incredibly broad range, which includes approved and certified raw materials to more than 2,000 extemporaneous medicines and more than 200 different stock preparations. We manufacture a lot of vital drugs that, for the individual patient, can mean the difference between life and death. In many cases, we follow patients over periods of many years, having started manufacturing extemporaneous medicines for them as children and then adjusting their dosage as they grow older,” says Erik Haeffler. ERIK HAEFFLER CEO OF APL Apotek Produktion & Laboratorier Website: apl.se NORDICLIFESCIENCE.ORG 3